Lecanemab vs Trontinemab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Alzheimer's Disease

Shared mechanism: Amyloid-beta (monoclonal antibody) · full Alzheimer's Disease pipeline

Lecanemab · Leqembi

Marketed by Eisai and partners

Approved in Alzheimer's Diseasemonoclonal antibody
Partial signal

NCT01767311 · Phase 2 · completed

Randomized, triple-masked phase 2b in early Alzheimer's disease (856 participants). The Bayesian primary analysis of the ADCOMS composite at 12 months estimated a 63.8% posterior probability of meaningful benefit for the highest dose, short of the study's prespecified success criterion, so the primary endpoint was not met.

Next expected readout: December 2026 · NCT06602258 (registry estimate)

Reported efficacy

Core Study Phase: Change From Baseline in Alzheimer's Disease Composite Score (ADCOMS) at Month 12 (Core Study Phase: at Month 12); Core Study Phase: Number of Participants With All Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) (From first dose of the study drug (Week 1) up to 90 days after last dose of study drug (up to 21 months)); OLE Phase: Number of Participants With All TEAEs and SAEs (From first dose of the study drug (Week 1) up to 30 days after last dose of study drug (up to 61 months)): ADCOMS change from baseline at Month 12 (lower = less decline): lecanemab 10 mg/kg biweekly 0.077 and 10 mg/kg monthly 0.084 vs placebo 0.113; lower doses did not separate: 2.5 mg/kg biweekly 0.134, 5 mg/kg monthly 0.119, 5 mg/kg biweekly 0.116. (missed)

Result source: NCT01767311

Trontinemab

Developed by Roche

Phase 3 in Alzheimer's Diseasebispecific antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: July 2027 · NCT04639050 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Alzheimer's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLecanemabTrontinemab
CDR-SB, change1.2 vs 1.5−0.3 vs placebo10 mg/kg Monthly · wk 78 · n 246NCT01767311
9 other results
  • 1.1 vs 1.5 10 mg/kg Biweekly · wk 78 · n 152 · Phase 2 · secondary NCT01767311
  • 0.7 vs 0.9 10 mg/kg Monthly · wk 52 · n 246 · Phase 2 · secondary NCT01767311
  • 0.6 vs 0.9 10 mg/kg Biweekly · wk 52 · n 152 · Phase 2 · secondary NCT01767311
  • 1.7 vs 1.5 5 mg/kg Monthly · wk 78 · n 48 · Phase 2 · secondary NCT01767311
  • 1.5 vs 1.5 5 mg/kg Biweekly · wk 78 · n 89 · Phase 2 · secondary NCT01767311
  • 1.3 vs 0.9 5 mg/kg Monthly · wk 52 · n 48 · Phase 2 · secondary NCT01767311
  • 0.9 vs 0.9 5 mg/kg Biweekly · wk 52 · n 89 · Phase 2 · secondary NCT01767311
  • 1.2 vs 1.5 2.5 mg/kg Biweekly · wk 78 · n 52 · Phase 2 · secondary NCT01767311
  • 1.0 vs 0.9 2.5 mg/kg Biweekly · wk 52 · n 52 · Phase 2 · secondary NCT01767311
—Trial running · NCT07170150
ADAS-Cog11, change—Trial running · NCT01760005—Trial running · NCT07170150
ADCS-ADL, change—Trial running · NCT01760005—Trial running · NCT07170150
MMSE, change—Trial running · NCT01760005—Trial running · NCT07170150
Amyloid PET, change (centiloids)—Trial running · NCT01760005—Trial running · NCT07170150

CDR-SB, change

Lecanemab
1.2 vs 1.5−0.3 vs placebo10 mg/kg Monthly · wk 78 · n 246NCT01767311
9 other results
  • 1.1 vs 1.5 10 mg/kg Biweekly · wk 78 · n 152 · Phase 2 · secondary NCT01767311
  • 0.7 vs 0.9 10 mg/kg Monthly · wk 52 · n 246 · Phase 2 · secondary NCT01767311
  • 0.6 vs 0.9 10 mg/kg Biweekly · wk 52 · n 152 · Phase 2 · secondary NCT01767311
  • 1.7 vs 1.5 5 mg/kg Monthly · wk 78 · n 48 · Phase 2 · secondary NCT01767311
  • 1.5 vs 1.5 5 mg/kg Biweekly · wk 78 · n 89 · Phase 2 · secondary NCT01767311
  • 1.3 vs 0.9 5 mg/kg Monthly · wk 52 · n 48 · Phase 2 · secondary NCT01767311
  • 0.9 vs 0.9 5 mg/kg Biweekly · wk 52 · n 89 · Phase 2 · secondary NCT01767311
  • 1.2 vs 1.5 2.5 mg/kg Biweekly · wk 78 · n 52 · Phase 2 · secondary NCT01767311
  • 1.0 vs 0.9 2.5 mg/kg Biweekly · wk 52 · n 52 · Phase 2 · secondary NCT01767311
Trontinemab
—Trial running · NCT07170150

ADAS-Cog11, change

Lecanemab
—Trial running · NCT01760005
Trontinemab
—Trial running · NCT07170150

ADCS-ADL, change

Lecanemab
—Trial running · NCT01760005
Trontinemab
—Trial running · NCT07170150

MMSE, change

Lecanemab
—Trial running · NCT01760005
Trontinemab
—Trial running · NCT07170150

Amyloid PET, change (centiloids)

Lecanemab
—Trial running · NCT01760005
Trontinemab
—Trial running · NCT07170150
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Lecanemab: 4 of 4 rows · Trontinemab: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricLecanemabTrontinemab
Dropout rate
46%10 mg/kg Biweeklya
NCT01767311 · Phase 2
show 5 more results
38.7%10 mg/kg Monthly
NCT01767311 · Phase 2
—10 mg/kg Biweekly
NCT01767311 · Phase 2
33.7%5 mg/kg Biweekly
NCT01767311 · Phase 2
27.5%5 mg/kg Monthly
NCT01767311 · Phase 2
32.7%2.5 mg/kg Biweekly
NCT01767311 · Phase 2
0%7.2 mg/kga
NCT04023994 · Phase 1 · registry result, not featured evidence
show 4 more results
0%3.6 mg/kg
NCT04023994 · Phase 1 · registry result, not featured evidence
16.7%1.2 mg/kg
NCT04023994 · Phase 1 · registry result, not featured evidence
50%0.4 mg/kg
NCT04023994 · Phase 1 · registry result, not featured evidence
25%0.1 mg/kg
NCT04023994 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
7.5%10 mg/kg Biweeklya
NCT01767311 · Phase 2
show 5 more results
9.1%10 mg/kg Monthly
NCT01767311 · Phase 2
—10 mg/kg Biweekly
NCT01767311 · Phase 2
5.4%5 mg/kg Biweekly
NCT01767311 · Phase 2
3.9%5 mg/kg Monthly
NCT01767311 · Phase 2
7.7%2.5 mg/kg Biweekly
NCT01767311 · Phase 2
—7.2 mg/kga
NCT04023994 · Phase 1 · registry result, not featured evidence
show 4 more results
—3.6 mg/kg
NCT04023994 · Phase 1 · registry result, not featured evidence
—1.2 mg/kg
NCT04023994 · Phase 1 · registry result, not featured evidence
—0.4 mg/kg
NCT04023994 · Phase 1 · registry result, not featured evidence
—0.1 mg/kg
NCT04023994 · Phase 1 · registry result, not featured evidence
Serious AEs
15.5%10 mg/kg Biweeklya
NCT01767311 · Phase 2
show 5 more results
12.3%10 mg/kg Monthly
NCT01767311 · Phase 2
33.3%10 mg/kg Biweekly
NCT01767311 · Phase 2
17.4%5 mg/kg Biweekly
NCT01767311 · Phase 2
7.8%5 mg/kg Monthly
NCT01767311 · Phase 2
19.2%2.5 mg/kg Biweekly
NCT01767311 · Phase 2
0%7.2 mg/kga
NCT04023994 · Phase 1 · registry result, not featured evidence
show 4 more results
0%3.6 mg/kg
NCT04023994 · Phase 1 · registry result, not featured evidence
0%1.2 mg/kg
NCT04023994 · Phase 1 · registry result, not featured evidence
0%0.4 mg/kg
NCT04023994 · Phase 1 · registry result, not featured evidence
0%0.1 mg/kg
NCT04023994 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
10 mg/kg Biweeklya
infusion related reaction 19.3% (placebo 3.3%)
headache 14.3% (placebo 10.2%)
upper respiratory tract infection 11.8% (placebo 16.7%)
NCT01767311 · Phase 2
show 5 more results
10 mg/kg Monthly
infusion related reaction 23.3% (placebo 3.3%)
headache 17% (placebo 10.2%)
urinary tract infection 9.9% (placebo 13.1%)
NCT01767311 · Phase 2
10 mg/kg Biweekly
fall 26.1% (placebo 11.4%)
infusion related reaction 21.7% (placebo 3.3%)
urinary tract infection 18.9% (placebo 13.1%)
NCT01767311 · Phase 2
5 mg/kg Biweekly
headache 18.5% (placebo 10.2%)
urinary tract infection 18.5% (placebo 13.1%)
fall 14.1% (placebo 11.4%)
NCT01767311 · Phase 2
5 mg/kg Monthly
cerebral microhaemorrhage 13.7% (placebo 4.9%)
diarrhoea 13.7% (placebo 4.9%)
nasopharyngitis 13.7% (placebo 11.4%)
NCT01767311 · Phase 2
2.5 mg/kg Biweekly
headache 17.3% (placebo 10.2%)
upper respiratory tract infection 13.5% (placebo 16.7%)
diarrhoea 9.6% (placebo 4.9%)
NCT01767311 · Phase 2
7.2 mg/kga
infusion related reaction 100% (placebo 10%)
headache 50% (placebo 50%)
injection site extravasation 16.7% (placebo 0%)
NCT04023994 · Phase 1 · registry result, not featured evidence
show 4 more results
3.6 mg/kg
infusion related reaction 83.3% (placebo 10%)
nausea 33.3% (placebo 30%)
back pain 16.7% (placebo 0%)
NCT04023994 · Phase 1 · registry result, not featured evidence
1.2 mg/kg
headache 83.3% (placebo 50%)
back pain 50% (placebo 0%)
nausea 50% (placebo 30%)
NCT04023994 · Phase 1 · registry result, not featured evidence
0.4 mg/kg
back pain 25% (placebo 0%)
headache 25% (placebo 50%)
arthralgia 0% (placebo 10%)
NCT04023994 · Phase 1 · registry result, not featured evidence
0.1 mg/kg
back pain 75% (placebo 0%)
arthralgia 0% (placebo 10%)
chills 0% (placebo 0%)
NCT04023994 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Lecanemab

ADCOMS 0.084 vs 0.113 placebo score @ 52wk10 mg/kg Monthly
absolute change · score
NCT01767311 · Phase 2
show 9 more results
0.077 vs 0.113 placebo score @ 52wk10 mg/kg Biweekly
NCT01767311 · Phase 2
0.166 vs 0.193 placebo score @ 78wk10 mg/kg Monthly
NCT01767311 · Phase 2
0.136 vs 0.193 placebo score @ 78wk10 mg/kg Biweekly
NCT01767311 · Phase 2
0.119 vs 0.113 placebo score @ 52wk5 mg/kg Monthly
NCT01767311 · Phase 2
0.116 vs 0.113 placebo score @ 52wk5 mg/kg Biweekly
NCT01767311 · Phase 2
0.192 vs 0.193 placebo score @ 78wk5 mg/kg Monthly
NCT01767311 · Phase 2
0.199 vs 0.193 placebo score @ 78wk5 mg/kg Biweekly
NCT01767311 · Phase 2
0.134 vs 0.113 placebo score @ 52wk2.5 mg/kg Biweekly
NCT01767311 · Phase 2
0.173 vs 0.193 placebo score @ 78wk2.5 mg/kg Biweekly
NCT01767311 · Phase 2
Brain Amyloid Change Centiloids -41.704 vs -2.154 placebo centiloids @ 52wk10 mg/kg Monthly
absolute change · centiloids
NCT01767311 · Phase 2
show 9 more results
-62.827 vs -2.154 placebo centiloids @ 52wk10 mg/kg Biweekly
NCT01767311 · Phase 2
-53.412 vs 1.004 placebo centiloids @ 78wk10 mg/kg Monthly
NCT01767311 · Phase 2
-72.495 vs 1.004 placebo centiloids @ 78wk10 mg/kg Biweekly
NCT01767311 · Phase 2
-16.877 vs -2.154 placebo centiloids @ 52wk5 mg/kg Monthly
NCT01767311 · Phase 2
-37.796 vs -2.154 placebo centiloids @ 52wk5 mg/kg Biweekly
NCT01767311 · Phase 2
-31.168 vs 1.004 placebo centiloids @ 78wk5 mg/kg Monthly
NCT01767311 · Phase 2
-46.217 vs 1.004 placebo centiloids @ 78wk5 mg/kg Biweekly
NCT01767311 · Phase 2
-14.733 vs -2.154 placebo centiloids @ 52wk2.5 mg/kg Biweekly
NCT01767311 · Phase 2
-22.404 vs 1.004 placebo centiloids @ 78wk2.5 mg/kg Biweekly
NCT01767311 · Phase 2
CDR-SB 0.705 vs 0.911 placebo score @ 52wk10 mg/kg Monthly
absolute change · score
NCT01767311 · Phase 2
show 9 more results
0.568 vs 0.911 placebo score @ 52wk10 mg/kg Biweekly
NCT01767311 · Phase 2
1.248 vs 1.499 placebo score @ 78wk10 mg/kg Monthly
NCT01767311 · Phase 2
1.102 vs 1.499 placebo score @ 78wk10 mg/kg Biweekly
NCT01767311 · Phase 2
1.277 vs 0.911 placebo score @ 52wk5 mg/kg Monthly
NCT01767311 · Phase 2
0.945 vs 0.911 placebo score @ 52wk5 mg/kg Biweekly
NCT01767311 · Phase 2
1.713 vs 1.499 placebo score @ 78wk5 mg/kg Monthly
NCT01767311 · Phase 2
1.463 vs 1.499 placebo score @ 78wk5 mg/kg Biweekly
NCT01767311 · Phase 2
1.038 vs 0.911 placebo score @ 52wk2.5 mg/kg Biweekly
NCT01767311 · Phase 2
1.227 vs 1.499 placebo score @ 78wk2.5 mg/kg Biweekly
NCT01767311 · Phase 2
ADAS-Cog 2.2 vs 2.842 placebo score @ 52wk10 mg/kg Monthly
absolute change · score
NCT01767311 · Phase 2
show 9 more results
1.481 vs 2.842 placebo score @ 52wk10 mg/kg Biweekly
NCT01767311 · Phase 2
4.624 vs 4.902 placebo score @ 78wk10 mg/kg Monthly
NCT01767311 · Phase 2
2.588 vs 4.902 placebo score @ 78wk10 mg/kg Biweekly
NCT01767311 · Phase 2
3.426 vs 2.842 placebo score @ 52wk5 mg/kg Monthly
NCT01767311 · Phase 2
3.297 vs 2.842 placebo score @ 52wk5 mg/kg Biweekly
NCT01767311 · Phase 2
5.746 vs 4.902 placebo score @ 78wk5 mg/kg Monthly
NCT01767311 · Phase 2
4.506 vs 4.902 placebo score @ 78wk5 mg/kg Biweekly
NCT01767311 · Phase 2
4.251 vs 2.842 placebo score @ 52wk2.5 mg/kg Biweekly
NCT01767311 · Phase 2
5.574 vs 4.902 placebo score @ 78wk2.5 mg/kg Biweekly
NCT01767311 · Phase 2
Brain Amyloid Change Centiloids -10.136 centiloids @ 13wk10 mg/kg Monthly
absolute change · centiloids
Extension (open-label)
No placebo or comparator arm
NCT01767311 · Phase 2
show 17 more results
-27.575 centiloids @ 13wk10 mg/kg Biweekly
NCT01767311 · Phase 2
-21.253 centiloids @ 26wk10 mg/kg Monthly
NCT01767311 · Phase 2
-21.606 centiloids @ 26wk10 mg/kg Biweekly
NCT01767311 · Phase 2
-27.927 centiloids @ 52wk10 mg/kg Monthly
NCT01767311 · Phase 2
-22.769 centiloids @ 52wk10 mg/kg Biweekly
NCT01767311 · Phase 2
-34.646 centiloids @ 104wk10 mg/kg Monthly
NCT01767311 · Phase 2
-30.715 centiloids @ 104wk10 mg/kg Biweekly
NCT01767311 · Phase 2
-40.367 centiloids @ 156wk10 mg/kg Monthly
NCT01767311 · Phase 2
-33.116 centiloids @ 156wk10 mg/kg Biweekly
NCT01767311 · Phase 2
-43.541 centiloids @ 208wk10 mg/kg Monthly
NCT01767311 · Phase 2
-32.976 centiloids @ 208wk10 mg/kg Biweekly
NCT01767311 · Phase 2
-18.26 centiloids @ 13wk
NCT01767311 · Phase 2
-32.208 centiloids @ 26wk
NCT01767311 · Phase 2
-50.951 centiloids @ 52wk
NCT01767311 · Phase 2
-60.3 centiloids @ 104wk
NCT01767311 · Phase 2
-65.243 centiloids @ 156wk
NCT01767311 · Phase 2
-66.598 centiloids @ 208wk
NCT01767311 · Phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lecanemab's landscape · Trontinemab's landscape